SCHEMBL4332115

SCHEMBL4332115

Cc1cc(C(=O)NCc2cc3ccccc3o2)cc2c(-c3cccc(F)c3)n[nH]c12

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.43
TTK P33981 2/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.39
KLKB1 P03952 3/20 0.39
MAPT P10636 1/20 0.39
HDAC2 Q92769 1/20 0.38
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
USP2 O75604 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ATM Q13315 1/20 0.36
TP53 P04637 1/20 0.36
AKR1C4 P17516 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4340581 0.92 CSNK1D (0.42) CSNK1DTTKPTGDR2HDAC2HPGD
SCHEMBL4332464 0.90 CSNK1D (0.41) CSNK1DPTGDR2MAPTHPGDSMN1; SMN2
SCHEMBL4334638 0.85 HPGD (0.42) CSNK1DTTKKLKB1MAPTHPGD
SCHEMBL4336101 0.84 HPGD (0.57) HPGDSMN1; SMN2
SCHEMBL4334043 0.82 PTGDR2 (0.42) CSNK1DPTGDR2KLKB1MAPTHDAC2
SCHEMBL4334969 0.80 TTK (0.54) TTKMAPTHPGDSMN1; SMN2USP2
SCHEMBL4345594 0.79 HPGD (0.42) CSNK1DTTKMAPTHPGDSMN1; SMN2
SCHEMBL4333979 0.77 MAPT (0.43) CSNK1DTTKMAPTHPGDSMN1; SMN2
SCHEMBL4348128 0.77 ALDH1A1 (0.45) MAPTHPGDSMN1; SMN2HSD17B10TP53
SCHEMBL4336397 0.76 HPGD (0.61) HPGDSMN1; SMN2ALOX15HSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CSNK1D 134/4885TTK 1201/4885PTGDR2 1870/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CSNK1D 134/4885TTK 1201/4885PTGDR2 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.